No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 51,286 | 51,469 | 51,750 | 51,384 | 56,610 | 59,187 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 2,000 | 7,484 | 6,891 | 7,515 | 9,317 | 9,350 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Japan Lifeline Co., Ltd. is a medical technology firm based in Japan that specializes in cardiovascular healthcare devices. Its operations encompass research, manufacturing, global procurement, and sales of these specialized medical instruments within the country. The company's diverse product range includes solutions for cardiac rhythm management, such as pacemakers, implantable cardioverter defibrillators (including subcutaneous models), cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support tools. For electrophysiology and ablation procedures, Japan Lifeline offers various electrophysiological and ablation catheters (like irrigated tip versions), endoscopic balloon ablation systems, esophageal temperature monitors, internal atrial cardioversion systems, and radio-frequency transseptal needles. Furthermore, its portfolio extends to cardiovascular and endografting products, including vascular, open, and abdominal stent-grafts. In the transvascular intervention segment, the company provides PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and devices for closing atrial septal defects. Complementing these, its gastrointestinal intervention solutions encompass radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Established in 1981, Japan Lifeline Co., Ltd. maintains its headquarters in Tokyo, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Japan Lifeline Co., Ltd. (7575.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Japan Lifeline Co., Ltd. is a medical technology firm based in Japan that specializes in cardiovascular healthcare devices. Its operations encompass research, manufacturing, global procurement, and sales of these specialized medical instruments within the country. The company's diverse product range includes solutions for cardiac rhythm management, such as pacemakers, implantable cardioverter defibrillators (including subcutaneous models), cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support tools. For electrophysiology and ablation procedures, Japan Lifeline offers various electrophysiological and ablation catheters (like irrigated tip versions), endoscopic balloon ablation systems, esophageal temperature monitors, internal atrial cardioversion systems, and radio-frequency transseptal needles. Furthermore, its portfolio extends to cardiovascular and endografting products, including vascular, open, and abdominal stent-grafts. In the transvascular intervention segment, the company provides PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and devices for closing atrial septal defects. Complementing these, its gastrointestinal intervention solutions encompass radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Established in 1981, Japan Lifeline Co., Ltd. maintains its headquarters in Tokyo, Japan.
